Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 4/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.45 |
| ▸ | GRB2 | P62993 | 1/20 | 0.45 |
| ▸ | CIB1 | Q99828 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21303808 | 0.97 | PLG (0.49) | KRASHDAC4OXTRHDAC3HDAC1 | |
| SCHEMBL30928172 | 0.97 | PLG (0.49) | KRASHDAC4OXTRHDAC3HDAC1 | |
| SCHEMBL29773718 | 0.97 | PLG (0.49) | KRASHDAC4OXTRHDAC3HDAC1 | |
| SCHEMBL29884013 | 0.97 | PLG (0.49) | KRASHDAC4OXTRHDAC3HDAC1 | |
| SCHEMBL29740322 | 0.97 | PLG (0.49) | KRASHDAC4OXTRHDAC3HDAC1 | |
| SCHEMBL30038886 | 0.97 | PLG (0.49) | KRASHDAC4OXTRHDAC3HDAC1 | |
| SCHEMBL29773738 | 0.95 | PLG (0.52) | KRASHDAC4OXTRHDAC3HDAC1 | |
| SCHEMBL29773704 | 0.91 | KRAS (0.49) | KRASHDAC4OXTRHDAC3HDAC1 | |
| SCHEMBL29390495 | 0.91 | KRAS (0.49) | KRASHDAC4OXTRHDAC3HDAC1 | |
| SCHEMBL29884109 | 0.91 | KRAS (0.49) | KRASHDAC4OXTRHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295748-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SPOREGEN LIMITED (GB) | 2025-09-25 | — | — | US | claimed |
| EP-3755357-B1 | AN ANTIBIOTIC COMPOSITION COMPRISING MICELLES | SPOREGEN LTD (GB) | 2025-09-17 | — | — | EP | claimed |
| US-12171734-B2 | Pathogenic bacteria | SPOREGEN LIMITED (GB) | 2024-12-24 | — | — | US | claimed |
| EP-4208181-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SporeGen Limited (GB) | 2023-07-12 | — | — | EP | claimed |
| WO-2022049381-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SPOREGEN LIMITED (GB) | 2022-03-10 | — | — | WO | claimed |
| US-20250295748-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SPOREGEN LIMITED (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-3755357-B1 | AN ANTIBIOTIC COMPOSITION COMPRISING MICELLES | SPOREGEN LTD (GB) | 2025-09-17 | — | — | EP | disclosed |
| US-12171734-B2 | Pathogenic bacteria | SPOREGEN LIMITED (GB) | 2024-12-24 | — | — | US | disclosed |
| CN-116437933-A | Treatment and prevention of viral infections | 孢子原有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4208181-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SporeGen Limited (GB) | 2023-07-12 | — | — | EP | disclosed |
| CN-114668009-A | Biostimulant compositions comprising lipopeptides for plant growth | 利波法布里克公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-110312425-B | Biostimulant compositions comprising lipopeptides for plant growth | 利波法布里克公司 | 2022-05-03 | — | — | CN | disclosed |
| WO-2022049381-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SPOREGEN LIMITED (GB) | 2022-03-10 | — | — | WO | disclosed |
| US-20200375931-A1 | PATHOGENIC BACTERIA | SPOREGEN LIMITED (GB) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171734-B2 | Pathogenic bacteria | CLPP, CLPX, ANTXR2 | KRAS 3299/4885HDAC4 379/4885OXTR 4744/4885 |
| US-20250295748-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | TLR3, TLR5, IRF3 | KRAS 2371/4885HDAC4 1528/4885OXTR 4718/4885 |
| US-20200375931-A1 | PATHOGENIC BACTERIA | CLPP, CLPX, ANTXR2 | KRAS 3299/4885HDAC4 379/4885OXTR 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.